Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$22.71 -1.0%	$18.84	$13.40 ▼ $25.23	$3.84B	0.65	1.96 million shs	6.66 million shs
APLS Apellis Pharmaceuticals	$17.69 -0.4%	$18.18	$16.10 ▼ $42.47	$2.23B	0.68	2.35 million shs	2.09 million shs
EXAI Exscientia	$4.84	$4.97	$3.80 ▼ $6.49	$632.93M	0.83	666,220 shs	N/A
IBRX ImmunityBio	$2.87 +1.1%	$2.67	$1.83 ▼ $7.63	$2.51B	0.14	6.10 million shs	9.12 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-1.05%	+4.61%	+3.94%	+35.26%	+52.72%
APLS Apellis Pharmaceuticals	-0.39%	-6.05%	+1.55%	-26.72%	-55.85%
EXAI Exscientia	0.00%	0.00%	0.00%	0.00%	-6.20%
IBRX ImmunityBio	+1.06%	-6.51%	+8.30%	+5.90%	-53.93%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.6571 of 5 stars	3.3	1.0	0.0	2.6	4.2	2.5
APLS Apellis Pharmaceuticals	4.6977 of 5 stars	4.3	3.0	4.4	3.3	2.5	0.6
EXAI Exscientia	0.2951 of 5 stars	1.0	0.0	0.0	1.1	1.7	0.6
IBRX ImmunityBio	2.3569 of 5 stars	3.6	2.0	0.0	2.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.69	Moderate Buy	$26.79	17.95% Upside
APLS Apellis Pharmaceuticals	2.62	Moderate Buy	$40.05	126.41% Upside
EXAI Exscientia	2.00	Hold	$5.00	3.31% Upside
IBRX ImmunityBio	3.20	Buy	$12.25	326.83% Upside

Current Analyst Ratings Breakdown

Latest EXAI, ACAD, IBRX, and APLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$26.00 ➝ $30.00
6/5/2025	ACAD ACADIA Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/5/2025	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Hold	$18.00 ➝ $23.00
6/4/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/2/2025	APLS Apellis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$26.00 ➝ $29.00
5/28/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/22/2025	APLS Apellis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$49.00 ➝ $41.00
5/21/2025	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$20.00 ➝ $35.00
5/20/2025	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $24.00
5/20/2025	IBRX ImmunityBio	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$4.25 ➝ $5.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	3.97	$0.70 per share	32.56	$4.40 per share	5.16
APLS Apellis Pharmaceuticals	$781.37M	2.85	N/A	N/A	$1.84 per share	9.61
EXAI Exscientia	$25.60M	24.72	N/A	N/A	$2.54 per share	1.91
IBRX ImmunityBio	$14.74M	171.85	N/A	N/A	($0.57) per share	-5.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.37	16.58	29.88	4.91	22.97%	17.46%	10.75%	8/5/2025 (Estimated)
APLS Apellis Pharmaceuticals	-$197.88M	-$1.79	N/A	N/A	N/A	-28.83%	-99.19%	-25.35%	7/30/2025 (Estimated)
EXAI Exscientia	-$181.56M	-$1.51	N/A	N/A	N/A	-882.09%	-49.10%	-33.13%	N/A
IBRX ImmunityBio	-$413.56M	-$0.58	N/A	N/A	N/A	-1,310.30%	N/A	-121.88%	8/11/2025 (Estimated)

Latest EXAI, ACAD, IBRX, and APLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	IBRX ImmunityBio	-$0.12	-$0.15	-$0.03	-$0.15	$17.50 million	$16.52 million
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million
5/7/2025	Q1 2025	APLS Apellis Pharmaceuticals	-$0.36	-$0.74	-$0.38	-$0.74	$197.61 million	$149.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EXAI Exscientia	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.88	2.80
APLS Apellis Pharmaceuticals	2.76	4.08	3.62
EXAI Exscientia	0.06	4.54	4.54
IBRX ImmunityBio	N/A	2.22	2.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
APLS Apellis Pharmaceuticals	96.29%
EXAI Exscientia	41.58%
IBRX ImmunityBio	8.58%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
APLS Apellis Pharmaceuticals	6.50%
EXAI Exscientia	16.40%
IBRX ImmunityBio	76.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	123.01 million	Optionable
APLS Apellis Pharmaceuticals	770	125.68 million	117.51 million	Optionable
EXAI Exscientia	280	130.77 million	109.32 million	Optionable
IBRX ImmunityBio	590	882.62 million	204.86 million	Optionable

EXAI, ACAD, IBRX, and APLS Headlines

Recent News About These Companies

ImmunityBio (NASDAQ:IBRX) Stock Price Down 5.9% - Here's Why

June 17, 2025 | marketbeat.com

ImmunityBio (NASDAQ:IBRX) Shares Gap Down - Here's Why

June 13, 2025 | marketbeat.com

ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze

June 13, 2025 | seekingalpha.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $670,000 Position in ImmunityBio, Inc. (NASDAQ:IBRX)

June 12, 2025 | marketbeat.com

ImmunityBio (IBRX) Jumps 18% on Anktiva Access Expansion

June 10, 2025 | msn.com

ImmunityBio (NASDAQ:IBRX) Shares Gap Up - Still a Buy?

June 9, 2025 | marketbeat.com

15 Stocks That Stole The Show Last Week

June 8, 2025 | insidermonkey.com

Millennium Management LLC Reduces Position in ImmunityBio, Inc. (NASDAQ:IBRX)

June 8, 2025 | marketbeat.com

Why ImmunityBio, Inc. (IBRX) Skyrocketed Today

June 5, 2025 | insidermonkey.com

ImmunityBio (NASDAQ:IBRX) Trading Up 6.3% - Should You Buy?

June 4, 2025 | marketbeat.com

HC Wainwright Reiterates Buy Rating for ImmunityBio (NASDAQ:IBRX)

June 4, 2025 | marketbeat.com

ImmunityBio (NASDAQ:IBRX) Shares Gap Up - Here's Why

June 3, 2025 | marketbeat.com

ImmunityBio receives FDA Expanded Access authorization for Cancer BioShield

June 3, 2025 | finance.yahoo.com

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

June 3, 2025 | businesswire.com

ImmunityBio (NASDAQ:IBRX) Receives Buy Rating from D. Boral Capital

June 3, 2025 | marketbeat.com

ImmunityBio gets FDA expanded access authorization to treat lymphopenia with Anktiva

June 2, 2025 | msn.com

ImmunityBio Sees Unusually Large Options Volume (NASDAQ:IBRX)

June 2, 2025 | marketbeat.com

Deutsche Bank AG Reduces Stock Position in ImmunityBio, Inc. (NASDAQ:IBRX)

June 1, 2025 | marketbeat.com

ImmunityBio (NASDAQ:IBRX) Trading 6.3% Higher - Time to Buy?

May 30, 2025 | marketbeat.com

Why ImmunityBio, Inc. (IBRX) Surged On Thursday

May 30, 2025 | msn.com

ImmunityBio's (IBRX) Buy Rating Reaffirmed at D. Boral Capital

May 29, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXAI, ACAD, IBRX, and APLS Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$22.71 -0.24 (-1.05%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$22.64 -0.07 (-0.33%)

As of 06/20/2025 07:08 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Apellis Pharmaceuticals NASDAQ:APLS

$17.69 -0.07 (-0.39%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$17.68 -0.01 (-0.06%)

As of 06/20/2025 06:15 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Exscientia NASDAQ:EXAI

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

ImmunityBio NASDAQ:IBRX

$2.87 +0.03 (+1.06%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.88 +0.01 (+0.52%)

As of 06/20/2025 07:58 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time